688246 Goodwill E-Health Info
- 16.06
- +0.06+0.38%
Goodwill E-Health Info News
Haitong International: The order for August has improved, with a recovery in medical IT demand.
In August, there was a significant improvement in the number and amount of large orders, indicating a strong demand for medical IT construction. The cumulative situation of winning bids in 2024 is stable.
Jiahe Meikang (688246): Computer Securities Research Report / Company Commentary
Investment event: The company released the interim report for 2024. The revenue scale reached 0.3 billion yuan, a year-on-year increase of 2.92%, and the net income attributable to the parent company was a loss of 0.027 billion yuan. Income grew slightly, and the gross margin improved. During the reporting period, the company's medical
Jiahe Meikang (688246): Short-term performance under pressure, AI medical large-scale model landing validation.
Investment Highlights: Event: The company released its 2024 interim report, achieving revenue of 0.3 billion yuan in 24H1, a year-on-year increase of 2.92%. Achieved net income attributable to shareholders of -0.027 billion yuan, compared to -0.023 billion in 23H1.
Jiahe Meikang (688246): Steady growth in 24H1 revenue and outstanding progress in specialist products.
Key points: The revenue in 24H1 shows a steady and gradual growth trend, and the performance is mainly under pressure due to the losses of subsidiary companies. The company released its 2024 interim report, with revenue of 0.3 billion yuan in 2024H1, a year-on-year increase of 2.9%, with a net total revenue of
Jahe Beauty (688246): Short-term pressure due to the impact of subsidiary restructuring, continuous optimization of cost control.
The company's performance in the first half of the year was under pressure due to the restructuring of its subsidiaries. After strengthening internal management, the gross profit margin has improved and expenses have been well controlled. We are bullish on the further release of the demand for electronic medical record construction, and the company's performance is expected to experience rapid growth, as well as the company's AI+ medical.
Jiahe Meikang 2024 Semi-Annual Report
Jiahe Meikang's summary of the 2024 interim report.
Jiahe Meikang (688246.SH) released its first-half financial report, with a net loss of 27.4722 million yuan and an expanded loss.
Jiahe Meikang (688246.SH) released its first half-year results, with revenue of 0.3 billion yuan, a year-on-year increase of 2.92%...
As of July 10th, there were 5,220 shareholders of Jiahe Meikang (688246.SH).
On July 29th, Gelunhui reported that as of the close of July 10th, 2024, Jiahe Meikang (688246.SH) had 5,220 shareholders on its investor platform.
Jiahe Meikang (688246): Building a full-closed-loop medical data system and opening a new chapter in medical AI.
As a leading company in healthcare informatization, this company has prominent advantages in the field. Its business covers core areas of healthcare informatization such as electronic medical record systems, hospital datacenters, and intelligent healthcare solutions, providing comprehensive services for medical facilities.
As of June 20, 2024, there are 5,744 shareholders in Jiahe Meikang (688246.SH).
On June 26th, Gelonhui reported that as of June 20th, 2024, Jiahe Meikang (688246.SH) had 5,744 shareholders.
Jiahe Meikang (688246.SH): Has repurchased 0.72% of the company's shares.
Jiahe Meikang (688246.SH) announced on June 3 that as of May 31, 2024, the company has cumulatively repurchased 1,004,378 shares through the Shanghai Stock Exchange trading system by centralized bidding, accounting for 0.72% of the company's total share capital. The highest and lowest repurchase transaction prices were 35.00 yuan/share and 18.93 yuan/share, respectively. The total amount paid was RMB 30,038,020.15 (excluding stamp duty, transaction fees and other charges).
Kahoku Meikang Annual Report 2023 (updated version)
Jiahe Meikang (688246): Significant year-on-year loss reduction in 24Q1 and high R&D investment to enhance product competitive advantage
Affected by the pace of the hospital's recruitment business, 23 years of performance were under pressure. The company discloses its 2023 annual report. In 2023, the company achieved revenue of 695 million yuan, a year-on-year decrease of 3.04%, mainly due to the impact of the pace of hospital recruitment business; net return to mother
Express News | Science and Technology Innovation Board Review: Science and Technology Innovation 50 Index closed up 0.9%, and the photovoltaic sector gained strength
Express News | Jin Tongling's financial fraud case involving Dahua was suspended for 6 months, and 15 A-share listed companies announced the cancellation of cooperation with them in the past 2 days
Jiahe Meikang (688246.SH): As of May 10, 2024, the number of shareholders in the company was 6033
Gelonghui, May 13 | Jiahe Meikang (688246.SH) said on an interactive platform that as of May 10, 2024, the number of shareholders of the company was 6033.
Jiahe Meikang (688246): 2024Q1 performance recovery, big model products are expected to be unveiled soon
Investment Highlights: Event: On April 27, 2024, Jiahe Meikang released its 2023 financial report and 2024 quarterly report. In 2023, the company achieved revenue of 695 million yuan, a year-on-year decrease of 3.04%, achieving
Express News | Jiahe Meikang: Saifu Puxin plans to reduce holdings by no more than 2%
Jiahe Meikang (688246): 23 years of performance under pressure, 24Q1 performance verification pressure lifted
The 23-year results are under pressure, mainly due to the negative impact of external supervision on the hospital recruitment business. The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 700 million yuan, a year-on-year decrease of 3
Analysis
Price Target
No Data
No Data